ReviewJournal of experimental & clinical cancer research : CR2026
Cadherin 17 and digestive cancers: from diagnostic to therapeutic opportunities.
Review in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CaAntibodies (Basel, Switzerland) · 2026Article
- A Novel Anti-Cadherin-17 Monoclonal Antibody, CaAntibodies (Basel, Switzerland) · 2026Article
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadherin-17 (CDH17, LI-cadherin) is a non-classical cadherin with restricted expression in normal gastrointestinal epithelium, emerging as a multifunctional molecule in cancer. CDH17 regulates cell–cell adhesion, modulates key signaling pathways, and interacts with the tumor microenvironment, collectively influencing proliferation, invasion, metastasis, therapeutic resistance, and immune evasion. Its expression is highly context-dependent and dynamically regulated, with both upregulation and loss linked to distinct features of tumor aggressiveness and differentiation. CDH17 also interfaces with pathways governing stemness and cellular plasticity, suggesting a role in modulating therapeutic response and resistance mechanisms.Beyond its biological functions, CDH17 has been investigated as a diagnostic marker, with tissue-based detection, circulating biomarkers, and radiolabeled imaging probes exploiting its tumor-restricted expression and membrane localization, offering opportunities for noninvasive tumor detection, staging, and monitoring. CDH17 also holds potential prognostic significance, although its clinical relevance varies according to molecular context and tumor differentiation status, emphasizing the need for integrative biomarker assessment. Finally, the tumor-specific expression of CDH17 has inspired multiple therapeutic strategies, including cellular immunotherapies, antibody–drug conjugates, immunotoxins, radiolabeled agents, and engineered delivery platforms, all designed to selectively target CDH17-expressing cells while minimizing off-target toxicity. Such strategies highlight the translational potential of CDH17 as both a therapeutic target and a platform for precision oncology.In this review, we summarize the molecular mechanisms, biological functions, diagnostic and prognostic relevance, and therapeutic applications of CDH17. By integrating current findings and addressing existing challenges, we aim to provide a comprehensive overview of its multifaceted roles and to emphasize emerging strategies to harness this molecule for clinical applications in cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.